HLB's fourth rivoceranib filing hinges on two factories' FDA inspection ratings

The first two reviews had raised manufacturing concerns about camrelizumab, the Hengrui immunotherapy paired with rivoceranib as a first-line treatment for unresectable or metastatic liver cancer ^[6][2]. Manufacturing figured in all three rejections ^[5][6]. The Korea Herald ties the pattern to HLB's reliance on its Chinese partner to meet US standards ^[6]. Both factory ratings speak to that problem. The FDA classed Hengrui's active pharmaceutical ingredient plant as Voluntary Action Indicated in July, and the finished-drug plant received the same rating earlier this month ^[7][8].

VAI means inspectors found issues that call for voluntary correction but did not recommend formal regulatory action. According to the Korea Herald, the rating neither guarantees approval nor rules out further FDA questions ^[9]. The API rating arrived in the same month as the third rejection ^[7][5], so the finished-drug rating is the newer information. The report describes the two inspected sites as linked to rivoceranib ^[10]. It does not say whether the camrelizumab concerns from the first two reviews were resolved separately.

Lyrfigtu's approval tests a different skill. An official at a Korean pharmaceutical firm told the Korea Herald the experience "could help the company manage regulatory submissions and respond to FDA requests more effectively in future applications," then added: "it does not mean rivoceranib will receive the same treatment, as the two drugs have different targets, indications and regulatory dossiers" ^[14]. Handling FDA requests well counts for something in a fourth review. The problems that sank the first three were in manufacturing ^[5][6].

Shareholders paid for Lyrfigtu anyway. A 30% gain after a 30% loss leaves a share at 91% of where it started (0.7 x 1.3) ^[17]. Three limit-down sessions and one limit-up compound to 0.7 x 0.7 x 0.7 x 1.3, or about 45% ^[15]. Leave out every other trading day and those four sessions alone took more than half the share price from anyone who held through all of them.

Elevar is preparing the resubmission with the same partner. "Elevar will soon finish the preparations for resubmitting the liver cancer drug's (new drug application) in close cooperation with Jiangsu Hengrui Pharmaceuticals and thoroughly deal with the FDA's review," an HLB official said ^[11]. HLB Group Chairman Jin Yang-gon put the liver cancer drug inside a wider promise. "Starting with Lyrfigtu, we will sequentially deliver more achievements, including treatments for liver cancer, keratitis, and CAR-T therapies, to prove the value of HLB Group in the global market," he said ^[19].

Three outcomes are open. The FDA can accept the file with both ratings holding through review. It can raise new questions on the dossier, something VAI does not rule out ^[9]. Or the camrelizumab concerns from the earlier reviews can come back ^[6]. We think the fourth attempt ^[16] is more credible than the third because of the two plant ratings, and that Lyrfigtu adds little to it. A rejection citing any Hengrui facility, or a reason outside manufacturing, would show the ratings were not the whole problem.